Govcon Giants


Text 786-477-0477

Pfizer Inc. Awarded $5.2B for 10 million doses of Pfizer’s oral protease inhibitor drug PF-07321332

 In Contract Awards

Pfizer Inc., New York, New York, was awarded a $5,295,000,000 firm-fixed-price contract for 10 million doses of Pfizer’s oral protease inhibitor drug PF-07321332. Bids were solicited via the internet with 10 received. Work will be performed in New York, New York, with an estimated completion date of March 31, 2023. Fiscal 2021 CARES Act and Paycheck Protection Program and Health Care Enhancement Act funds in the amount of $5,295,000,000 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W58P05-22-C-0001). (Awarded Nov. 17, 2021)

Pfizer Inc. is one of the world’s largest research-based pharmaceuticals firm, producing medicines for cardiovascular health, metabolism, oncology, inflammation and immunology, and other areas, with about 10 products that fetch approximately $1 billion or more in annual revenue. Its top prescription products include cholesterol-lowering Lipitor, pain management drugs Celebrex and Lyrica, pneumonia vaccine Prevnar, and erectile dysfunction treatment Viagra, as well as arthritis drug Enbrel, antibiotic Zyvox, and blood-thinner Eliquis. The company also makes and sells generic drugs and consumer health products. Pfizer operates around the world and gets about 55% of its revenue from international customers. (

Recommended Posts

Leave a Comment